Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IACH MATH 2020 | Amniotic membrane transplantation in ocular GvHD

Zinaida Perić • 25 Jun 2020
IACH MATH 2020
General Ibrutinib Ruxolitinib

Zinaida Perić, MD, PhD, University Hospital Centre Zagreb, School of Medicine, Zagreb, Croatia, outlines the use of amniotic membrane transplantation in the treatment of severe ocular graft-versus-host disease (GvHD). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Zinaida Perić

Advances in chronic GvHD management
2:34
Advances in chronic GvHD management
Zinaida Perić • 28 Sep 2021
Ibrutinib, ruxolitinib & belumosudil for SR-cGvHD
2:56
Ibrutinib, ruxolitinib & belumosudil for SR-cGvHD
Zinaida Perić • 28 Sep 2021
Next steps in chronic GvHD
2:13
Next steps in chronic GvHD
Zinaida Perić • 28 Sep 2021
Management of chronic GvHD
9:45
Management of chronic GvHD
Zinaida Perić • 25 Jun 2020

Related Videos

From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
2:58
From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
Iskra Pusic • 11 Sep 2026
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
3:46
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
Maher Salamoon • 8 Sep 2026
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
2:01
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
Michael Jain • 11 Sep 2026
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
1:46
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
Michael Jain • 11 Sep 2026
The content of VJHemOnc is intended for healthcare professionals